Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Oyster Point Pharma stock

OYST
US69242L1061
A2PTTE

Price

11.17
Today +/-
+0
Today %
+0 %
P

Oyster Point Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Oyster Point Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Oyster Point Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Oyster Point Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Oyster Point Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Oyster Point Pharma Stock Price History

DateOyster Point Pharma Price
1/12/202311.17 undefined
1/11/202311.17 undefined

Oyster Point Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oyster Point Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oyster Point Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oyster Point Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oyster Point Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oyster Point Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oyster Point Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oyster Point Pharma’s growth potential.

Oyster Point Pharma Revenue, EBIT and net profit per share

DateOyster Point Pharma RevenueOyster Point Pharma EBITOyster Point Pharma Net Income
2026e1.16 B undefined-109.03 M undefined-117.32 M undefined
2025e475.01 M undefined-80.59 M undefined-84.83 M undefined
2024e189.86 M undefined-46.61 M undefined-52.09 M undefined
2023e98.15 M undefined-85.23 M undefined-94.74 M undefined
2022e28.77 M undefined-158.53 M undefined-172.94 M undefined
202124.54 M undefined-96.66 M undefined-100.66 M undefined
20200 undefined-70.99 M undefined-70.52 M undefined
20190 undefined-47.3 M undefined-45.71 M undefined
20180 undefined-16.74 M undefined-16.5 M undefined
20170 undefined-5.68 M undefined-19.14 M undefined

Oyster Point Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201720182019202020212022e2023e2024e2025e2026e
00000.020.030.10.190.481.16
-----16.67250.0092.86151.32144.21
----95.83-----
00002300000
-5-16-47-70-96-158-85-46-80-109
-----400.00-564.29-86.73-24.34-16.84-9.40
-19-16-45-70-100-172-94-52-84-117
--15.79181.2555.5642.8672.00-45.35-44.6861.5439.29
20.6120.6121.3724.1326.0400000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Oyster Point Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Oyster Point Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20172018201920202021
         
22.35.2139.1192.6193.37
00006.66
00000
00006.09
0.90.433.89.14
23.25.6142.1196.4215.25
00.111.55.4
0000886
00000
00000
00000
000.10.11.08
00.11.11.67.37
23.25.7143.2198222.62
         
4343000.03
0.10.3221.5341.4354.92
-22-38.5-84.2-154.8-255.41
00000
00000
21.14.8137.3186.699.54
0.40.50.52.36.5
1.60.54.98.722.29
00000
00000
000016
215.41128.8
000089.82
00000
000.50.34.46
000.50.394.28
215.911.3123.08
23.15.8143.2197.9222.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Oyster Point Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Oyster Point Pharma's financial health and stability.

Assets

Oyster Point Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Oyster Point Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Oyster Point Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Oyster Point Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20172018201920202021
-6-16-45-70-100
00000
00000
0015-2
103613
00002
00000
-4-17-40-58-89
0000-1
0000-1
00000
00000
40000
21017411296
26017411291
-----4.00
00000
21-17133530
-4.67-17.08-41.02-59.1-90.86
00000

Oyster Point Pharma stock margins

The Oyster Point Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oyster Point Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oyster Point Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oyster Point Pharma's sales revenue. A higher gross margin percentage indicates that the Oyster Point Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oyster Point Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oyster Point Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oyster Point Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oyster Point Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oyster Point Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oyster Point Pharma Margin History

Oyster Point Pharma Gross marginOyster Point Pharma Profit marginOyster Point Pharma EBIT marginOyster Point Pharma Profit margin
2026e93.79 %-9.39 %-10.11 %
2025e93.79 %-16.97 %-17.86 %
2024e93.79 %-24.55 %-27.44 %
2023e93.79 %-86.83 %-96.52 %
2022e93.79 %-550.99 %-601.09 %
202193.79 %-393.88 %-410.2 %
202093.79 %0 %0 %
201993.79 %0 %0 %
201893.79 %0 %0 %
201793.79 %0 %0 %

Oyster Point Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Oyster Point Pharma earnings per share therefore indicates how much revenue Oyster Point Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oyster Point Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oyster Point Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oyster Point Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oyster Point Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oyster Point Pharma Revenue, EBIT and net profit per share

DateOyster Point Pharma Sales per ShareOyster Point Pharma EBIT per shareOyster Point Pharma Earnings per Share
2026e43.24 undefined0 undefined-4.37 undefined
2025e17.69 undefined0 undefined-3.16 undefined
2024e7.07 undefined0 undefined-1.94 undefined
2023e3.66 undefined0 undefined-3.53 undefined
2022e1.07 undefined0 undefined-6.44 undefined
20210.94 undefined-3.71 undefined-3.87 undefined
20200 undefined-2.94 undefined-2.92 undefined
20190 undefined-2.21 undefined-2.14 undefined
20180 undefined-0.81 undefined-0.8 undefined
20170 undefined-0.28 undefined-0.93 undefined

Oyster Point Pharma business model

Oyster Point Pharma Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company is headquartered in the San Francisco Bay Area and was founded in 2015. History: Oyster Point Pharma was founded by an experienced team of biologists and pharmaceutical experts. The company was supported by venture capital financing from leading venture capitalists. The founders' goal was to develop innovative therapies for eye diseases. In 2017, the company introduced a pipeline of therapies for various eye diseases based on the stimulation of tear flow, corneal nerves, and neurons. Since then, the company has expanded its pipeline and continues to invest significantly in the research and development of innovative therapies. Business model: Oyster Point Pharma has developed an innovative business model based on the development of therapies for eye diseases. The company utilizes its proprietary technology platform to identify new molecular targets and develop effective therapeutic options. The company works closely with leading scientists and clinics to develop and validate its pipeline of therapies. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Segments: Oyster Point Pharma focuses on developing innovative therapies for eye diseases. The company currently has three main products in its pipeline: OC-01, OC-02, and OC-03. OC-01 is a nasal spray based on the stimulation of tear flow. The product is currently in phase 3 clinical development for the treatment of patients with dry eye. Treatment with OC-01 is intended to increase the production and flow of tear fluid, thus relieving symptoms such as dryness, itching, and pain. OC-02 is a gel based on the stimulation of corneal nerves. The product is currently in phase 2 clinical development for the treatment of patients with neurotrophic keratitis. Treatment with OC-02 is intended to promote the regeneration of corneal nerves and accelerate the healing of the cornea. OC-03 is a nasal spray based on the stimulation of neurons in the nasal and oral areas. The product is currently in the preclinical development phase for the treatment of patients with acute glaucoma and has not yet been approved for use in humans. Products: Oyster Point Pharma currently has three main products in its pipeline: OC-01, OC-02, and OC-03. These products aim to develop innovative therapies for various eye diseases. The products utilize proprietary technologies to selectively stimulate tear flow, corneal nerves, and neurons. By developing these innovative therapies, the company aims to improve the vision and quality of life of patients. Summary: Oyster Point Pharma is an innovative biopharmaceutical company focused on the development of therapies for eye diseases. The company has developed a proprietary technology platform for the identification of new molecular targets and the development of effective therapeutic options. The company currently has three main products in its pipeline, aiming to develop innovative therapies for various eye diseases. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Oyster Point Pharma is one of the most popular companies on Eulerpool.com.

Oyster Point Pharma Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Oyster Point Pharma Revenue by Segment

Segmente2021
License revenue - related party18.39 M USD
Milestone revenue - related party5 M USD
Product revenue, net1.15 M USD
TYRVAYA Nasal Spray1.2 M USD

Oyster Point Pharma SWOT Analysis

Strengths

Oyster Point Pharma Inc has a strong research and development team dedicated to developing innovative therapies for ocular surface diseases.

The company has successfully conducted clinical trials, demonstrating the effectiveness of their products in improving patient outcomes.

Oyster Point Pharma Inc has established strategic partnerships with key industry players, enhancing their market reach and potential for growth.

Weaknesses

Oyster Point Pharma Inc is a relatively new company in the pharmaceutical industry and may face challenges in building brand recognition and trust among healthcare professionals and patients.

The company heavily relies on the success of their pipeline products, which may pose a risk if any of those products fail to achieve regulatory approval or meet market expectations.

Limited financial resources may hinder the company's ability to aggressively expand their operations and compete with well-established competitors.

Opportunities

The growing prevalence of ocular surface diseases worldwide presents a significant market opportunity for Oyster Point Pharma Inc to tap into.

Advancements in technology and medical research provide opportunities for the company to develop more effective and targeted therapies for ocular surface diseases.

Expansion into emerging markets presents new avenues for revenue growth and market expansion.

Threats

Intense competition from well-established pharmaceutical companies poses a threat to Oyster Point Pharma Inc's market share.

Regulatory challenges and stringent approval processes may delay the launch of new products and limit the company's ability to generate revenue.

Economic uncertainties and market volatilities can impact the investment climate, potentially affecting Oyster Point Pharma Inc's ability to secure funding for research and development.

Oyster Point Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Oyster Point Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Oyster Point Pharma shares outstanding

The number of shares was Oyster Point Pharma in 2023 — This indicates how many shares 26.037 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oyster Point Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oyster Point Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oyster Point Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oyster Point Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Oyster Point Pharma.

Oyster Point Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-1.56 -1.37  (11.98 %)2022 Q3
6/30/2022-1.69 -1.87  (-10.44 %)2022 Q2
3/31/2022-1.78 -1.8  (-1.27 %)2022 Q1
12/31/2021-1.42 -1.61  (-13.56 %)2021 Q4
9/30/2021-1.18 -0.68  (42.36 %)2021 Q3
6/30/2021-0.86 -0.85  (1.57 %)2021 Q2
3/31/2021-0.93 -0.73  (21.35 %)2021 Q1
12/31/2020-0.8 -0.86  (-7.18 %)2020 Q4
9/30/2020-0.75 -0.63  (16.16 %)2020 Q3
6/30/2020-0.82 -0.66  (19.62 %)2020 Q2
1
2

Oyster Point Pharma shareholders

%
Name
Stocks
Change
Date
7.61544 % RTW Investments L.P.2,044,312-14,1929/30/2022
6.72540 % Point72 Asset Management, L.P.1,805,387-83,7099/30/2022
6.14028 % Paradigm BioCapital Advisors LP1,648,316185,7409/30/2022
3.87278 % Kohlberg Kravis Roberts & Co. L.P.1,039,62209/30/2022
22.07279 % New Enterprise Associates (NEA)5,925,287011/7/2022
2.89457 % Telemark Asset Management, LLC777,02609/30/2022
2.10419 % GW&K Investment Management, LLC564,856100,4739/30/2022
13.62531 % Versant Ventures3,657,618-201,4741/5/2022
10.31350 % Invus Financial Advisors, LLC2,768,58609/30/2022
1.89908 % Cowen & Co., LLC509,79409/30/2022
1
2
3
4
5
...
10

Oyster Point Pharma Executives and Management Board

Dr. Jeffrey Nau47
Oyster Point Pharma President, Chief Executive Officer, Director
Compensation 2.8 M
Mr. Daniel Lochner
Oyster Point Pharma Chief Financial Officer, Chief Business Officer
Compensation 1.88 M
Mr. George Eliades52
Oyster Point Pharma Independent Director
Compensation 553,373
Mr. Donald Santel61
Oyster Point Pharma Independent Chairman of the Board
Compensation 354,471
Dr. Ali Behbahani46
Oyster Point Pharma Independent Director
Compensation 207,318
1
2
3

Oyster Point Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Pfizer Stock
Pfizer
SupplierCustomer0,400,76-0,210,47-0,39-0,81
1

Most common questions regarding Oyster Point Pharma

What values and corporate philosophy does Oyster Point Pharma represent?

Oyster Point Pharma Inc is committed to upholding a set of core values and a corporate philosophy that guides its operations. The company places a strong emphasis on innovation and scientific excellence to develop novel therapies. Oyster Point Pharma Inc also prioritizes patient-centricity by striving to meet the unmet needs of individuals with ocular surface diseases and ocular neurology disorders. The company believes in fostering a culture of collaboration and teamwork, aiming to build lasting relationships with patients, healthcare professionals, and stakeholders. Oyster Point Pharma Inc continuously strives to deliver value to its shareholders while maintaining high ethical standards and transparency in all aspects of its business.

In which countries and regions is Oyster Point Pharma primarily present?

Oyster Point Pharma Inc is primarily present in the United States.

What significant milestones has the company Oyster Point Pharma achieved?

Oyster Point Pharma Inc has achieved several significant milestones in its journey. The company successfully completed a Phase 2b clinical trial for its lead product candidate, OC-01 nasal spray, demonstrating positive results in treating dry eye disease. Oyster Point Pharma Inc also received Fast Track designation from the U.S. FDA for OC-01, highlighting the potential of this therapeutic approach. Furthermore, the company obtained FDA approval to initiate a Phase 3 clinical trial for OC-01, showcasing its commitment to advancing this novel treatment option for patients. Oyster Point Pharma Inc's achievements demonstrate its dedication to developing innovative solutions for ocular surface diseases.

What is the history and background of the company Oyster Point Pharma?

Oyster Point Pharma Inc is a pharmaceutical company specializing in the development and commercialization of therapies for ocular surface diseases. Founded in 2015, the company aims to address the unmet medical needs of patients suffering from dry eye disease. Their innovative therapies target neuroreceptors in the eye to stimulate tear production and improve ocular surface health. Oyster Point Pharma Inc has conducted extensive research and clinical trials to support the effectiveness and safety of their products. With a dedicated team of experts in the field, the company is committed to advancing treatment options for patients with ocular surface diseases, including dry eye.

Who are the main competitors of Oyster Point Pharma in the market?

The main competitors of Oyster Point Pharma Inc in the market are pharmaceutical companies that focus on developing therapies for dry eye disease and other ocular surface disorders. Some notable competitors include Novartis AG, Johnson & Johnson, Allergan, Alcon, and Santen Pharmaceutical Co., Ltd. These companies, like Oyster Point Pharma Inc, strive to address the unmet needs of patients suffering from ocular surface diseases through innovative treatments and therapies.

In which industries is Oyster Point Pharma primarily active?

Oyster Point Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Oyster Point Pharma?

Oyster Point Pharma Inc's business model focuses on the development and commercialization of innovative therapies for ocular surface diseases. The company is dedicated to providing effective and safe treatment options for individuals suffering from conditions such as dry eye disease. Oyster Point Pharma Inc leverages its expertise in neurostimulation and ophthalmology to develop novel therapies that target the underlying causes of these ocular surface diseases. By addressing the unmet needs of patients, Oyster Point Pharma Inc aims to improve the quality of life and vision for individuals worldwide.

What is the P/E ratio of Oyster Point Pharma 2024?

The Oyster Point Pharma P/E ratio is -5.58.

What is the P/S ratio of Oyster Point Pharma 2024?

The Oyster Point Pharma P/S ratio is 1.53.

What is the AlleAktien quality score of Oyster Point Pharma?

The AlleAktien quality score for Oyster Point Pharma is 3/10.

What is the revenue of Oyster Point Pharma 2024?

The expected Oyster Point Pharma revenue is 189.86 M USD.

How high is the profit of Oyster Point Pharma 2024?

The expected Oyster Point Pharma profit is -52.09 M USD.

What is the business model of Oyster Point Pharma

Oyster Point Pharma Inc is an innovative biopharmaceutical company focused on developing therapeutic treatments for patients with ophthalmological diseases. The company's main focus is on developing medications for the treatment of patients with Dry Eye and other anterior eye diseases. The business model of Oyster Point Pharma is based on identifying new treatment options for patients suffering from Dry Eye symptoms. The company has developed a range of patented technologies that allow it to quickly and cost-effectively develop and bring new medications to market. The company is divided into two business areas: Research and Development, and Marketing and Sales. In the Research and Development area, Oyster Point Pharma collaborates closely with a network of scientists and experts to develop new medications that are safe and effective. The company utilizes state-of-the-art technology and research platforms to quickly gain new insights and develop effective medications. In the Marketing and Sales area, Oyster Point Pharma focuses on successfully placing and selling its medications in the market. The company works with a network of distribution partners to ensure that its products are available in all key markets. The company focuses on supporting and training its distribution partners to ensure they are able to sell effectively and successfully. One key product of Oyster Point Pharma is OC-01 (varenicline), a medication for the treatment of patients with Dry Eye. The medication is a synthetic analog of acetylcholine, a naturally occurring neurotransmitter responsible for increasing tear fluid and salivary gland secretion. By increasing acetylcholine levels in the patient's body, OC-01 increases tear fluid, reducing Dry Eye symptoms. Oyster Point Pharma also has other promising drug candidates in the pipeline, including the medication OC-02 (nimento) for the treatment of anterior eye diseases, and OC-03, which is in preclinical development for the treatment of posterior eye diseases (macular degeneration). Overall, Oyster Point Pharma's business model is focused on becoming a leading provider of therapeutic treatments for patients with ophthalmological diseases. The company relies on advanced product innovation in research and development and an effective marketing and sales strategy. With its pipeline of promising drug candidates, Oyster Point Pharma has the potential to revolutionize the market for ophthalmic medications.

What is the Oyster Point Pharma dividend?

Oyster Point Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Oyster Point Pharma pay dividends?

The dividend cannot currently be calculated for Oyster Point Pharma or the company does not pay out a dividend.

What is the Oyster Point Pharma ISIN?

The ISIN of Oyster Point Pharma is US69242L1061.

What is the Oyster Point Pharma WKN?

The WKN of Oyster Point Pharma is A2PTTE.

What is the Oyster Point Pharma ticker?

The ticker of Oyster Point Pharma is OYST.

How much dividend does Oyster Point Pharma pay?

Over the past 12 months, Oyster Point Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oyster Point Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Oyster Point Pharma?

The current dividend yield of Oyster Point Pharma is .

When does Oyster Point Pharma pay dividends?

Oyster Point Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oyster Point Pharma?

Oyster Point Pharma paid dividends every year for the past 0 years.

What is the dividend of Oyster Point Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oyster Point Pharma located?

Oyster Point Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oyster Point Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oyster Point Pharma from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Oyster Point Pharma pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Oyster Point Pharma in the year 2023?

In the year 2023, Oyster Point Pharma distributed 0 USD as dividends.

In which currency does Oyster Point Pharma pay out the dividend?

The dividends of Oyster Point Pharma are distributed in USD.

All fundamentals about Oyster Point Pharma

Our stock analysis for Oyster Point Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oyster Point Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.